A Schuh1, P Foerster2, S Priglinger2, K Eibl-Lindner2,3. 1. Augenklinik, LMU, Mathildenstr. 8, 80336, München, Deutschland. anna.schuh@med.uni-muenchen.de. 2. Augenklinik, LMU, Mathildenstr. 8, 80336, München, Deutschland. 3. Augenärzte Pasinger Hofgärten, München, Deutschland.
Abstract
PURPOSE: Approach to loss of visual acuity in a patient with a choroidal osteoma (CO) which had been stable for seven years. METHODS: Fluorescence angiography confirmed a choroidal neovascularization (CNV) as the cause of the loss of visual acuity. Treatment with intravitreal (IVT) injection of ranibizumab. RESULTS: Increase of visual acuity and decrease of edema after IVT injection. CONCLUSION: Monitoring is necessary even for primarily benign CO in order to detect secondary complications causing loss of visual acuity, e. g. secondary CNV. Anti-VEGF IVT represents an approved treatment option.
PURPOSE: Approach to loss of visual acuity in a patient with a choroidal osteoma (CO) which had been stable for seven years. METHODS: Fluorescence angiography confirmed a choroidal neovascularization (CNV) as the cause of the loss of visual acuity. Treatment with intravitreal (IVT) injection of ranibizumab. RESULTS: Increase of visual acuity and decrease of edema after IVT injection. CONCLUSION: Monitoring is necessary even for primarily benign CO in order to detect secondary complications causing loss of visual acuity, e. g. secondary CNV. Anti-VEGF IVT represents an approved treatment option.
Authors: Mohammed A Khan; Francis C DeCroos; Philip P Storey; Jerry A Shields; Sunir J Garg; Carol L Shields Journal: Retina Date: 2014-09 Impact factor: 4.256
Authors: Carol L Shields; Sruthi Arepalli; Hatice T Atalay; Sandor R Ferenczy; Enzo Fulco; Jerry A Shields Journal: Retina Date: 2015-04 Impact factor: 4.256